Rabbit Polyclonal UBN1 antibody. Suitable for WB and reacts with Human samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human UBN1 aa 1050 to C-terminus.
View Alternative Names
Ubinuclein-1, HIRA-binding protein, Protein VT4, Ubiquitously expressed nuclear protein, UBN1
- WB
Unknown
Western blot - Anti-UBN1 antibody (AB101282)
All lanes:
Western blot - Anti-UBN1 antibody (ab101282) at 0.1 µg/mL
Lane 1:
HeLa whole cell lysate at 50 µg
Lane 2:
HeLa whole cell lysate at 15 µg
Lane 3:
HeLa whole cell lysate at 5 µg
Lane 4:
293T whole cell lysate at 50 µg
Predicted band size: 122 kDa
true
Exposure time: 3min
- WB
CiteAb
Western blot - Anti-UBN1 antibody (AB101282)
Western Blotting using Anti-UBN1 antibody, ab101282. Publication image from Ray-Gallet, D. et al., 2018, Nat Commun, 30082790. Legend direct from paper.
HIRA homooligomerizes in cells and forms a homotrimer in vitro. a YFP constructs of human HIRA and mutants. The WD40 repeat (aa 1–369), B (aa 439–475) and C (aa 763–963) domains involved in UBN, ASF1a, and CABIN1 interactions, respectively, are shown. Star indicates single amino acid substitution with alanine. The co-immunoprecipitation efficiency of endogenous HIRA or HIRA-HA (HIRA coIP) is indicated for each construct, “+” indicates that the efficiency of coIP is similar to the one obtained with the wt HIRA construct and “−” indicates that the efficiency of the coIP is decreased. b Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing YFP-tagged proteins. c Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing both YFP-tagged and HIRA-HA proteins. d Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing YFP-tagged proteins. In b, c and d, input corresponds to 10% of nuclear extract used for each experiment. e Equilibrium sedimentation of recombinant proteins HIRA(661–1017), CABIN1 full length (FL) and HIRA(661–1017) + CABIN1 FL. Theoretical (open symbols) and experimental (closed symbol) curves are shown
false
- WB
CiteAb
Western blot - Anti-UBN1 antibody (AB101282)
Western Blotting using Anti-UBN1 antibody, ab101282. Publication image from Ray-Gallet, D. et al., 2018, Nat Commun, 30082790. Legend direct from paper.
HIRA homooligomerization is required for CABIN1 interaction. a YFP constructs of human HIRA and mutants. The amino acids R227 and I461 critical for UBN and ASF1a interactions, respectively, are shown. Star indicates single amino acid substitution (R227 with K or I461 with D). The co-immunoprecipitation efficiencies of both endogenous HIRA (HIRA coIP) and CABIN1 (CABIN1 coIP) are indicated for each construct, “+” indicates that the efficiency of coIP is similar to the one obtained with the wt HIRA construct and “−” indicates that the efficiency of the coIP is decreased. b Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing YFP-tagged proteins. c Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing both HIRA-YFP and HIRA-HA proteins prepared from cells treated with siRNAs control or CABIN1. In b and c, input corresponds to 10% of nuclear extract used for each experiment
false
- WB
CiteAb
Western blot - Anti-UBN1 antibody (AB101282)
Western Blotting using Anti-UBN1 antibody, ab101282. Publication image from Ray-Gallet, D. et al., 2018, Nat Commun, 30082790. Legend direct from paper.
HIRA homooligomerization is required for CABIN1 interaction. a YFP constructs of human HIRA and mutants. The amino acids R227 and I461 critical for UBN and ASF1a interactions, respectively, are shown. Star indicates single amino acid substitution (R227 with K or I461 with D). The co-immunoprecipitation efficiencies of both endogenous HIRA (HIRA coIP) and CABIN1 (CABIN1 coIP) are indicated for each construct, “+” indicates that the efficiency of coIP is similar to the one obtained with the wt HIRA construct and “−” indicates that the efficiency of the coIP is decreased. b Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing YFP-tagged proteins. c Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing both HIRA-YFP and HIRA-HA proteins prepared from cells treated with siRNAs control or CABIN1. In b and c, input corresponds to 10% of nuclear extract used for each experiment
false
- WB
CiteAb
Western blot - Anti-UBN1 antibody (AB101282)
Western Blotting using Anti-UBN1 antibody, ab101282. Publication image from Ray-Gallet, D. et al., 2018, Nat Commun, 30082790. Legend direct from paper.
Homotrimerization of HIRA is critical for its enrichment at UV damaged sites and for new H3.3 deposition. a (Left, top) Scheme of the experimental assay for HIRA-YFP enrichment at local UV damage in U2OS cells. (Left, bottom) The graph shows the percentage of U2OS cells with HIRA-YFP protein colocalizing with XPB foci. Error bars represent SD from three independent experiments. Statistical analysis using a t-test was performed with Prism 7 software (ns : nonsignificant, *p < 0.05, ***p < 0.001). (Right) Images of representative U2OS cells irradiated locally with UV exhibiting an enrichment of HIRA wt or an absence of enrichment of HIRA (W799A–D800A) at one damage site identified by anti-XPB immunofluorescence. Scale bar 5 µm. b (Top, left) Scheme of the experimental assay for new H3.3 deposition by a Quench-Chase-Pulse experiment (QCP) in HeLa H3.3-SNAP-HA HIRA KO cells transfected with HIRA-HA constructs. (Top, right) Western blot analysis showing the protein expression of exogeneous HIRA-HA wt and (W799A–D800A) mutant. (Bottom, left) Images of cells subjected to QCP : representative images for a cell non-transfected or transfected with HIRA-HA (W799A–D800A) mutant and a high TMR positive representative image for a cell transfected with HIRA-HA wt. (Bottom, right). One graph shows the fluorescence intensity ratio TMR/TMR non-transfected. The other graph gives the percentage of cells exhibiting a positive profile for H3.3 deposition. Error bars represent the SD from three independent experiments. Statistical analysis using a t-test was performed with Prism 7 software (ns : nonsignificant, *p < 0.05)
false
- WB
CiteAb
Western blot - Anti-UBN1 antibody (AB101282)
Western Blotting using Anti-UBN1 antibody, ab101282. Publication image from Ray-Gallet, D. et al., 2018, Nat Commun, 30082790. Legend direct from paper.
Domains of HIRA involved in its homooligomerization and CABIN1 interaction are distinct. a YFP constructs of human HIRA and mutants. Three different structures matching the previously described C domain are indicated : β-strand (aa 661–872), loop (aa 873–904) andα-helical (aa 905–1017) domains. Star indicates single amino acid substitution with alanine. The co-immunoprecipitation efficiency of endogenous CABIN1 (CABIN1 coIP) is indicated for each construct, “+” indicates that the efficiency of coIP is similar to the one obtained with the wt HIRA construct and “−” indicates that the efficiency of the coIP is decreased. b Western blot analysis of anti-GFP-immunoprecipitates from U2OS nuclear extracts expressing YFP-tagged proteins. Input corresponds to 10% of nuclear extract used for each experiment. c (Left) Western blot analysis of nuclear extracts from HIRA KO and control HeLa cells. (Right) Western blot analysis of nuclear extracts from HeLa HIRA KO cells expressing YFP-tagged proteins. d Superose 6 fractionation of recombinant proteins CABIN1 FL, CABIN1 FL + HIRA(661–1017) and CABIN1 FL + HIRA(661–1017) δ873–904. The dashes indicate the fractions in which free CABIN1 FL elutes. Input corresponds to protein at the concentration that it was loaded onto the Superose 6 column. e Equilibrium sedimentation of recombinant protein HIRA(661–1017) δ873–904. Theoretical (open symbols) and experimental (closed symbol) curves are shown
false
Reactivity data
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
UBN1 acts as a participant in the regulation of gene expression. It is a component of the Human Histone Acetyltransferase complex (HBO1 complex) which modifies chromatin by adding acetyl groups to histones enabling a more open chromatin state. This more open state is important for gene transcription and DNA replication. UBN1's role in this complex is significant for the regulation of genes important for cell cycle progression and other essential cellular functions.
Pathways
Various control processes converge at UBN1. It plays a significant role in the epigenetic pathway influencing gene expression through chromatin modification. UBN1 is involved in the DNA replication initiation pathway where it facilitates the assembly of pre-replicative complexes. In these pathways UBN1 is related to proteins such as MCM2-7 which are essential for unwinding DNA during replication.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (5)
Recent publications for all applications. Explore the full list and refine your search
Cell reports 43:114964 PubMed39509271
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature structural & molecular biology 27:1152-1164 PubMed33046907
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nature structural & molecular biology 27:1057-1068 PubMed32895554
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 9:3103 PubMed30082790
2018
Applications
Unspecified application
Species
Unspecified reactive species
Molecular endocrinology (Baltimore, Md.) 29:1426-39 PubMed26305679
2015
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com